株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Polyphor Ltd. :製品パイプライン分析

Polyphor Ltd - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 253788
出版日 ページ情報 英文 39 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
Polyphor Ltd. :製品パイプライン分析 Polyphor Ltd - Product Pipeline Review - 2016
出版日: 2016年12月21日 ページ情報: 英文 39 Pages
概要

Polyphor Ltd. は、循環器疾患、感染症、腫瘍学、呼吸器疾患、免疫学、遺伝性疾患などといったいわゆる7大治療領域と未公表の疾患に対する有望な臨床薬候補を有しています。同社がこれらの化合物の開発に力を入れているのは、こうした疾患の症状は大きな市場ニーズがあり、その治療のための化合物によって患者は新たな便益を受けられる可能性があり、そして製薬会社間との提携に価値を生み出すことができるためです。

当レポートでは、Polyphor Ltd. における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Polyphor Ltd.の基本情報

  • Polyphor Ltd.の概要
  • 主要情報
  • 企業情報

Polyphor Ltd.:R&Dの概要

  • 主な治療範囲

Polyphor Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Polyphor Ltd.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Polyphor Ltd.:薬剤プロファイル

  • POL-6326
  • POL-5551
  • POL-6014
  • POL-6926
  • POL-7080 Follow-On
  • POL-7085
  • Small Molecule for Undisclosed Indication
  • Small Molecules for Infectious Diseases
  • Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology
  • Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology

Polyphor Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Polyphor Ltd.:最近のパイプライン動向

Polyphor Ltd.:休止中のプロジェクト

Polyphor Ltd.:本社と子会社の所在地

付録

図表

目次
Product Code: GMDHC08172CDB

Summary

Global Markets Direct's,'Polyphor Ltd - Product Pipeline Review - 2016', provides an overview of the Polyphor Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Polyphor Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Polyphor Ltd
  • The report provides overview of Polyphor Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Polyphor Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Polyphor Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Polyphor Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Polyphor Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Polyphor Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polyphor Ltd Snapshot
    • Polyphor Ltd Overview
    • Key Facts
  • Polyphor Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Polyphor Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Polyphor Ltd - Pipeline Products Glance
    • Polyphor Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Polyphor Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Polyphor Ltd - Drug Profiles
    • balixafortide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-5551 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-6014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-6926 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7080 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7080 Follow-On - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Unspecified Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Agonize FPR1/2 for Immunology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Antagonize FPR1/2 for Immunology and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polyphor Ltd - Pipeline Analysis
  • Polyphor Ltd - Pipeline Products by Target
  • Polyphor Ltd - Pipeline Products by Route of Administration
  • Polyphor Ltd - Pipeline Products by Molecule Type
  • Polyphor Ltd - Pipeline Products by Mechanism of Action
  • Polyphor Ltd - Dormant Projects
  • Polyphor Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • POL-7080
  • Polyphor Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Polyphor Ltd, Key Facts
  • Polyphor Ltd - Pipeline by Indication, 2016
  • Polyphor Ltd - Pipeline by Stage of Development, 2016
  • Polyphor Ltd - Monotherapy Products in Pipeline, 2016
  • Polyphor Ltd - Partnered Products in Pipeline, 2016
  • Polyphor Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Polyphor Ltd - Phase II, 2016
  • Polyphor Ltd - Phase I, 2016
  • Polyphor Ltd - Preclinical, 2016
  • Polyphor Ltd - Discovery, 2016
  • Polyphor Ltd - Pipeline by Target, 2016
  • Polyphor Ltd - Pipeline by Route of Administration, 2016
  • Polyphor Ltd - Pipeline by Molecule Type, 2016
  • Polyphor Ltd - Pipeline Products by Mechanism of Action, 2016
  • Polyphor Ltd - Dormant Developmental Projects,2016
  • Polyphor Ltd - Discontinued Pipeline Products, 2016

List of Figures

  • Polyphor Ltd - Pipeline by Top 10 Indication, 2016
  • Polyphor Ltd - Pipeline by Stage of Development, 2016
  • Polyphor Ltd - Monotherapy Products in Pipeline, 2016
  • Polyphor Ltd - Pipeline by Target, 2016
  • Polyphor Ltd - Pipeline by Route of Administration, 2016
  • Polyphor Ltd - Pipeline by Molecule Type, 2016
  • Polyphor Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top